摘要
[目的]探讨替米沙坦对非酒精性脂肪性肝病患者肝纤维化、血管内皮功能和炎症因子的影响。[方法]选取我院2015年1月~2016年10月收治的非酒精性脂肪性肝病92例,根据患者入院诊治时间顺序,随机将92例患者分为对照组和观察组,每组各46例。观察组采用替米沙坦进行治疗,对照组采用维生素E进行治疗。比较2组患者治疗3个月后肝纤维化、血管内皮功能和炎症因子变化情况及不良反应。[结果]在治疗3个月后,2组患者BMI指数较治疗前未出现明显变化(P>0.05);2组患者ET-1、HOMA-IR、hs-CRP、IL-6、CⅣ、PCⅢ、TG、ALT指标水平较治疗前有明显差异(P<0.05);对照组FMD为(8.63±1.62)%,显著低于观察组[(11.25±1.02)%,P<0.05],ET-1为(159.63±9.85)ng/L,显著高于观察组[(95.66±10.05)%,P<0.05],HOMA-IR为(3.89±0.75)%,显著高于观察组[(3.25±0.51)%,P<0.05],hs-CRP为(13.57±2.21)mg/L,显著高于观察组[(17.69±5.51)%,P<0.05],TNF-α为(30.26±4.02)mg/L,显著高于观察组[(13.65±6.23)%,P<0.05],IL-6为(30.26±4.02)ng/L,显著低于观察组[(15.23±3.59)ng/L,P<0.05],HA为(258.63±9.56)μg/L,显著低于观察组[(102.65±6.12)μg/L,P<0.05],CⅣ为(253.11±12.07)μg/L,显著高于观察组[(89.64±7.56)μg/L,P<0.05],PCⅢ为(180.15±5.39)μg/L,显著高于观察组[(121.02±5.03)μg/L,P<0.05],LN为(164.52±8.52)μg/L,显著高于观察组[(75.15±5.61)μg/L,P<0.05],TG为(1.98±1.10)mmol/L,显著高于观察组[(1.62±0.76)mmol/L,P<0.05],ALT为(68.36±12.21)U/L,显著高于观察组[(52.32±13.45)U/L,P<0.05],FPG为(5.12±0.61)mmol/L,显著高于观察组[(54.81±0.50)mmol/L,P<0.05];2组患者治疗过程中均未出现严重不良反应情况。[结论]替米沙坦治疗非酒精性脂肪性肝病可有改善患者肝纤维化、血管内皮功能,并降低炎症因子水平。
[Objective]To investigate the effects of Telmisartan on hepatic fibrosis,vascular endothelial function and inflammatory factors in patients with nonalcoholic fatty liver disease.[Methods]92 cases with nonalcoholic fatty liver disease in our hospital from January 2015 to October 2016 were selected.According to the time of admission,92 patients were randomly divided into two groups：the control group and the observation group.The patients in the observation group was treated with telmisartan and the patients in the control group was treated with vitamin E.The changes of hepatic fibrosis,vascular endothelial function and inflammatory factors and adverse reactions were respectively,compared between the two groups after 3 months of treatment.[Results]After three months of treatment,the BMI of the two groups showed no significant change compared with the BMI before treatment（P〉0.05）.The levels of HOMA IR,ET-1,hsCRP,IL-6,CⅣ,PCⅢ,TG and ALT in two groups after treatment had obvious difference compared withthe levels before treatment（P〈0.05）.The FMD in control group was（8.63±1.62）%,which was significantly lower than that in observationgroup[（11.25±1.02）%,P〈0.05],The ET-1 in control group was（159.63±9.85）ng/L,which was significantly higher than that in observation group[（95.66±10.05）%,P〈0.05].The HOMA-IR in control group was（3.89±0.75）%,which was significantly higher than that in observation group[（3.25±0.51）%,P〈0.05].The hs-CRP in control group was（13.57±2.21）mg/L,which was significantly higher than that in the observation group[（17.69±5.51）%,P〈0.05],The TNF-αin control group was（30.26±4.02）mg/L,which was significantly higher than that in the observation group[（13.65±6.23）%,P〈0.05].The IL-6 in control group was（30.26±4.02）ng/L,which was significantly lower than that in the observation group[（15.23±3.59）ng/L,P〈0.05].The HA in control group was（258.63±9.56）μg/L,which was significantly lower than that in the observation[（102.65±
作者
罗成福
刘姝
冯燕
李柳
LUO Cheng- fu;LIU Shu;FENG Yah;LI Liu(Department of Gastroenterology,the Affiliated Hospital of Panzhihua University, Siehuan 617000,China)
出处
《中国中西医结合消化杂志》
CAS
2018年第3期248-251,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
关键词
替米沙坦
非酒精性脂肪性肝病
肝纤维化
血管内皮功能
炎症因子
Telmisartan
nonalcoholic fatty liver disease
hepatic fibrosis
vascular endothelial functioninflammatory factors
